Genentech, a member of the Roche Group (RHHBY), announced the FDA has approved a label extension for Evrysdi to include babies under two months old with spinal muscular atrophy. Evrysdi is now approved to treat spinal muscular atrophy in children and adults of all ages.
The company noted that, as part of the label extension, the Evrysdi prescribing information has been updated to include recent two-year pooled data from parts 1 and 2 of the FIREFISH study, which showed long-term efficacy and safety in symptomatic infants with Type 1 SMA.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.